Arada's AED 2 billion move on Reem Hospital shows strategics are now a live exit route for scalable healthcare groups
A UAE developer just put AED 2 billion into a hospital. If you own a scalable healthcare brand, your buyer list is longer than you think.
What a board member needs before the next meeting on this.
- A developer bought a hospital. Arada took 80%+ of Reem with an AED 2bn commitment, for recurring, non-cyclical revenue against a cyclical development book.
- Strategics pay for a different reason than funds. They buy capability they cannot build quickly and a revenue stream they will hold, not a 3-5 year exit multiple.
- Your buyer list is longer than you think. Developers, insurers, facilities groups and regional operators each value your platform through a different lens.
- Founder continuity is leverage, not an afterthought. A buyer scaling your platform needs you, which lets you stage the exit and keep meaningful upside.
On 7 May 2026, Arada, one of the UAE's larger master developers, agreed to take a controlling stake of more than 80% in Abu Dhabi's Reem Hospital, buying out a shareholder consortium that included Investcorp and its affiliates. The founders, Zaid Al Siksek and Mansur Ali, kept a stake and stayed on to run the business. Arada attached an AED 2 billion (about USD 544 million) long-term commitment covering the equity and the expansion behind it. The precise price for the stake was not disclosed, and no EV/EBITDA multiple was published. What matters for you is not the headline figure. It is who wrote the cheque.
A developer bought a hospital. Read that again if you own a healthcare group and still picture your buyer universe as private equity funds and sovereign platforms. Arada's own framing was blunt: it wanted recurring, non-cyclical revenue to sit against a development book that rises and falls with the property cycle. Healthcare delivers exactly that. Reem is a post-acute rehabilitation and multi-specialty hospital that opened on Reem Island in 2020, and by 2025 it carried an 800-plus workforce, 120 doctors across 42 specialties, and more than 850,000 patient visits in a single year. That is a cash-generating platform with a demographic tailwind, and it is precisely the profile a developer needs to smooth its earnings.
The strategic buyer pays for a different reason than a fund does
A financial sponsor underwrites your group against an exit three to five years out and prices the multiple it expects to sell at. A strategic like Arada is buying capability it cannot build quickly on its own, and it is buying a revenue stream it will hold. Arada's plan is to roughly double the Reem Island flagship to around 200 beds, add three more hospitals across Abu Dhabi, Dubai and Sharjah, and build out a network of Reem Clinics. It is not acquiring a hospital. It is acquiring the operating spine for a healthcare arm it intends to scale. When a buyer thinks that way, the assets on your balance sheet matter less than the platform you have proven you can run.
This widens your competitive tension, and tension is what sets price
The instinct for most owners preparing an exit is to build a shortlist of the obvious regional funds and one or two strategics in the same clinical vertical. That list is too short. A developer assembling an integrated community, an insurer moving into provision, a facilities group chasing annuity income, a regional operator buying its way into a new emirate: each values your group through a different lens, and each will defend a different number. The Reem deal is a signal that the pool of credible acquirers for a well-run, scalable healthcare brand in the Gulf is deeper than the conventional map suggests. Running a process that reaches all of them, rather than the three you already know, is often the difference between a fair price and a full one.
Founder continuity was part of the structure, not an afterthought
Al Siksek and Mansur Ali retained equity and kept operational control. A strategic buying a platform it plans to expand needs the people who built it, and that need is your leverage. It lets you convert a clean exit into a staged one, take real money off the table now, and keep meaningful upside in the network the buyer is about to fund. If your group is genuinely scalable, a strategic will often pay you partly to stay, because your continued involvement is what de-risks their expansion thesis. That is a negotiating position most owners leave unused because they never model it.
None of this changes the discipline the numbers demand
Arada is buying scale, margin quality and a management team it trusts, and it will diligence all three hard. A group with thin governance, key-person concentration, or margins that do not survive scrutiny will not attract a developer's premium regardless of how attractive the exit route looks in a headline. The route is now open. Walking it well still requires a group that is genuinely investable and a process built to make several distinct types of buyer compete.
Four questions before you run a process
- Have we mapped every credible buyer type, or only the obvious regional funds?
- What capability or revenue stream would a strategic pay a premium to acquire from us?
- Can we structure founder continuity to take money off the table now and keep upside?
- Do our governance, margins and key-person risk survive a strategic's diligence?
If you own a scalable hospital or multi-site medical-center group and want to understand which strategics, not only funds, would actually pay up for it, Avior runs sell-side processes built to surface that full buyer set.